Transaction DateRecipientSharesTypePriceValue
16th October 2020David Sidransky16,667Exercise of derivative$5.46$91,001.82
16th October 2020David Sidransky10,100Payment by withholding$9.01$91,001.00
20th May 2020David Sidransky10Open or private purchase$6.98$69.80
13th May 2020David Sidransky70Open or private purchase$5.96$417.20
12th May 2020David Sidransky90Open or private purchase$5.90$531.00
7th May 2020David Sidransky10Open or private purchase$5.42$54.20
11th June 2018Yaron Adler37,662Conversion of derivative$0.00
Orgenesis logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.

Orgenesis, Inc. engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company was founded on June 5, 2008 by Sarah Ferber and is headquartered in Germantown, MD.

Ticker: ORGS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1460602
Employees: 309
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $97 M (91009%)
Inventory, Net: $176 Th (29%)
Assets, Current: $104 M (33%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $802 Th (2191%)
Assets: $119 M (28%)
Accounts Payable, Current: $2 M (-70%)
Liabilities, Current: $20 M (-53%)
Other Liabilities, Noncurrent: $284 Th (-14%)
Liabilities: $31 M (-44%)
Common Stock, Value, Issued: $2 Th (0%)
Common Stock, Shares, Issued: $22 M (36%)
Additional Paid in Capital, Common Stock: $123 M (29%)
Retained Earnings (Accumulated Deficit): $34 M (-61%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $10 Th (-95%)
Stockholders' Equity (Parent): $88 M (1510%)
Liabilities and Equity: $119 M (28%)
Revenue: $1 M (-48%)
Research and Development: $25 M (-15%)
Operating Income/Loss: $27 M (-20%)
Provision for income taxes: $12 Th (-65%)
EPS (basic): $0.95 (0%)
EPS (diluted): $0.95 (0%)